Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kuanxin Ningji granule is a traditional Chinese medicine (TCM) formulation developed by the Jiangsu Province Hospital of Integration of Chinese and Western Medicine. It is primarily indicated for the treatment of ventricular premature contractions (VPC). As a botanical combination, it is designed to address cardiac arrhythmias and is often evaluated in clinical settings as an adjunctive therapy to conventional Western treatments, such as beta-blockers like metoprolol. The granule aims to reduce the frequency of premature beats and improve symptoms associated with heart palpitations by potentially modulating cardiac ion channels and autonomic tone, reflecting the multi-target approach characteristic of herbal medicine. Clinical evaluation is ongoing to assess its safety and efficacy in adult patients with VPC.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kuanxin Ningji granule.